Alcami, a contract development and manufacturing organisation (CDMO), announced on Tuesday that it has completed Phase II of its cGMP biostorage facility situated in Amherst, New Hampshire.
The company's 104,000 square feet area is now completely operational and supports various cGMP storage requirements. The whole site covers a total area of 160,000 square feet.
The company is planning to complete phase III in the first quarter of 2023 and will add an additional 56,000 square feet of new capacity.
Spinogenix reveals positive SPG302 topline results from Phase 2a study for treatment of ALS
iLeukon reports FDA clearance of IND application for phase II study of ILKN421H in advanced NSCLC
AVEO Oncology signs development and option agreement with HiberCell
Merck assumes full development rights for investigational antibody MK-8690
UCB's KYGEVVI receives FDA approval for TK2d treatment
Camurus launches Oczyesa in Germany for patients with acromegaly
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Kiora Pharmaceuticals joins Global Genes' RARE-X Vision Consortium
Pilatus Biosciences to present new preclinical data on PLT012 at SITC 2025
Rovia Clinical Research opens new clinical research site in Hattiesburg, Mississippi